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ABSTRACT
Development of anti-cancer drugs towards clinical application is costly and 
inefficient. Large screens of drugs, efficacious for non-cancer disease, are currently 
being used to identify candidates for repurposing based on their anti-cancer properties. 
Here, we show that low-dose salinomycin, a coccidiostat ionophore previously 
identified in a breast cancer screen, has anti-leukemic efficacy. AML and MLLr cell 
lines, primary cells and patient samples were sensitive to submicromolar salinomycin. 
Most strikingly, colony formation of normal hematopoietic cells was unaffected by 
salinomycin, demonstrating a lack of hemotoxicity at the effective concentrations. 
Furthermore, salinomycin treatment of primary cells resulted in loss of leukemia 
repopulation ability following transplantation, as demonstrated by extended recipient 
survival compared to controls. Bioinformatic analysis of a 17-gene signature identified 
and validated in primary MLLr cells, uncovered immunomodulatory pathways, hubs 
and protein interactions as potential transducers of low dose salinomycin treatment. 
Additionally, increased protein expression of p62/Sqstm1, encoded for by one of 
the 17 signature genes, demonstrates a role for salinomycin in aggresome/vesicle 
formation indicative of an autophagic response.
Together, the data support the efficacy of salinomycin as an anti-leukemic at 
non-hemotoxic concentrations. Further investigation alone or in combination with 
other therapies is warranted for future clinical trial.
INTRODUCTION
Drug repurposing (or repositioning) has become a 
tactic to deploy approved weaponry in the war on cancer, 
resulting in the development of defined projects [1]. The 
concept of drug repurposing is borne from a demand to 
complement and accelerate current drug development 
strategies, which are often costly, inefficient, [2, 3] and 
in the case of anti-cancer therapies, can take over 8 years 
to obtain approval for clinical use [4]. This potential drug 
development ‘crisis’ is occurring at the same time as 
increased cancer incidence due in part to an aging society, 
altered lifestyles and diet in developing countries [5, 6].
Salinomycin is a polyether organic anion that is 
widely used as a coccidiostatic antibiotic in poultry and 
ruminant feed. Salinomycin was identified in a chemical 
screen by Gupta et al to target breast cancer stem cells 
(CSCs) [7], and has subsequently shown anti-neoplastic 
properties in a range of human cancers, including 
hematological malignancies (reviewed by Zhou et al) [8], 
though it’s activity in acute leukemia remains unexplored. 
We previously used Connectivity Mapping to identify 
candidate drugs, including an antibiotic, for repurposing 
as anti-leukemic agents [9].
As an antibiotic, salinomycin primarily acts as an 
ionophore, facilitating transportation of cations (e.g. Ca2+ and 
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K+) across membranes resulting in toxic intracellular levels 
[10, 11]. As an anti-cancer agent, salinomycin has been 
reported to activate several pathways including apoptosis 
in a p53/Caspase/CD95/DC95L/ proteasome independent 
manner, increase DNA damage, and inhibit Wnt signalling, 
preferentially in malignant CSCs [12–15]. However, the 
precise mechanism of action of salinomycin in distinct 
CSCs remains to be elucidated. One recognized limitation 
for clinical application of salinomycin is a relatively narrow 
therapeutic index, giving rise to potential related toxicities 
[16–18] and potential impairment of normal stem cell 
function, particularly within the hematopoietic system.
To gain further insight into possible clinical 
application for hematological malignancies, we examined 
and demonstrated the anti-leukemic potential of low-
dose salinomycin in pre-clinical models of acute myeloid 
leukemia (AML) and poor prognosis Mixed Lineage 
Leukemia-rearranged (MLLr) subtypes, whilst concurrently 
demonstrating negligible toxicity to normal blood cells.
RESULTS
Differential sensitivity of human AML cell lines 
to Salinomycin
AML cell lines demonstrated reduced cell viability 
following salinomycin treatment (100 nM - 5 μM), with 
OCI-AML3 cells demonstrating greatest and U937 cells 
least sensitivity, particularly at the 24 hour time point 
(Figure 1A and Supplementary Table S1). Reduced cell 
viability was associated with an accumulation of cells in the 
Sub G
0
 phase of the cell cycle as determined by direct DNA 
staining (Figure 1B) with only limited related changes in 
Caspase activity (Supplementary Figure S1, upper panel). 
Although U937 cells demonstrated little increase in the Sub 
G
0
 population, some alteration in cell cycle progression, 
primarily reduction of cells in S-phase, was observed.
To further examine the effects of salinomycin, AML 
cells were exposed to low concentrations (≤1 μM) for 48 
hours and examined microscopically. Three of the cell 
lines demonstrated significant alterations in morphology 
in a dose-dependent manner, ranging from loss of nuclear 
shape at low dose exposure (100 nM, HL60) to the 
formation of cytoplasmic vesicles at higher dosages (500 
nM, OCI-AML3, HL60 and NB4). Consistent with the cell 
viability and cell cycle assays, U937 cells demonstrated 
no morphological changes compared to DMSO controls 
(Figure 1C).
Salinomycin alters growth and morphology of 
MLLr cell lines
All four MLLr cell lines were sensitive to 
salinomycin over the same dose and time used for the 
AML cell lines, indicative of a biological response (Figure 
2A and Supplementary Table S1). Increases in Sub G
0
 
were associated with decreases in S-phase populations 
(Figure 2B and Supplementary Figure S2 upper), and 
increased Annexin V expression (Supplementary Figure 
S2) was associated with limited change in Caspase 
activity, restricted to 1 μM treatment of MV4;11 cells 
(Supplementary Figure S1, lower panel). Microscopic 
examination showed similar morphological changes as 
observed for AML cells, including the presence of vesicles 
in all MLLr cell lines following 500 nM salinomycin 
treatments (Figure 2C). Overt vesicle formation in three 
of the MLLr cell lines examined (MOLM-13, NOMO-1 
and RS4;11) was observed even at 100 nM salinomycin 
compared to vehicle controls, indicating increased 
sensitivity in these cell lines.
Salinomycin-sensitive primary murine AML and 
MLLr leukemia cell lines
To further examine the potential anti-leukemic 
effect of salinomycin, studies were extended into two 
growth factor-dependent primary murine cell lines 
A9M and MAF9, generated by retroviral transduction 
of HOXA9-ires-Meis1(A9M) or MLL-AF9 (MAF9) into 
primary haematopoietic cells, as previously reported 
[9], followed by serial replating in methylcellulose. 
Due to anticipated increased sensitivity in the primary 
cells, an extended lower dose range (10 - 500 nM) was 
used. Both primary cell lines demonstrated reduced cell 
viability at 250 nM and 500 nM salinomycin at both early 
(24 hour) and late (72 hour) time points (Figure 3A). 
Lower dose salinomycin (75 nM and 100 nM) resulted 
in differential time and cell line response, with the MAF9 
cells demonstrating greater sensitivity and lower estimated 
IC50s (Supplementary Figure S3). The decreased cell 
viability was matched with dramatic changes in cell cycle, 
in particular increased Sub G
0
 and decreased S and G2M 
populations at higher doses (Figure 3B). Consistent with 
the cell viability assays, cell cycle responses were more 
striking in MAF9 (lower panel) than A9M cells (upper 
panel). Since higher doses of salinomycin resulted in 
significant cell loss, cell morphology analysis in A9M 
and MAF9 cells was restricted to lower concentrations 
(75 nM and 100 nM) for up to 72 hours. Morphological 
changes, including the presence of vesicles, were observed 
for both cell lines in a time and dose-dependent manner. 
Interestingly, MAF9 cells also demonstrated the presence 
of band neutrophils at the 72 hour time point (75 nM), 
indicative of differentiation (Figure 3C).
Salinomycin-induced differential gene expression
Illumina BeadArray based gene expression profiling 
was carried out following low dose (75 nM and 100 nM) 
salinomycin treatment of MAF9 cells, the most sensitive 
primary mouse cell line examined (Supplementary 
Table S2). Overall output was characterized by plotting 
Oncotarget3www.impactjournals.com/oncotarget
Figure 1: Differential sensitivity of human AML cell lines to salinomycin. A. Bar graphs showing decreased viability in AML 
cell lines over time following salinomycin treatment at the indicated dosage compared to 0.01% DMSO vehicle control. B. Bar graphs 
showing altered cell cycle (Propidium Iodide staining) in AML cell lines over time following salinomycin treatment at the indicated dosage 
or 0.01% DMSO vehicle control. C. Representative morphology images of AML cell lines treated for 48 hours with salinomycin at the 
indicated dosages or 0.01% DMSO. Mean values ± S.E.M. of biological replicates (n=3) are plotted throughout. ***P < 0.001, **P < 0.01, 
*P < 0.05, t-test. Scale bar = 4 μm.
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Figure 2: Salinomycin alters growth and morphology of MLLr cell lines. A. Bar graphs showing decreased viability in MLLr 
cell lines over time following salinomycin treatment at the indicated dosage compared to 0.01% DMSO vehicle control. B. Bar graphs 
showing altered cell cycle (Propidium Iodide staining) in MLLr cell lines over time following salinomycin treatment at the indicated dosage 
or 0.01% DMSO vehicle control. C. Representative morphology images of MLLr cell lines treated for 48 hours with salinomycin at the 
indicated dosages or 0.01% DMSO. Mean values ± S.E.M. of biological replicates (n=3) are plotted throughout. ***P < 0.001, **P < 0.01, 
*P < 0.05, t-test. Scale bar = 4 μm.
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Figure 3: Salinomycin-sensitive primary murine AML and MLLr leukemia cell lines. A. Bar graphs showing decreased 
viability in A9M and MAF9 primary leukemia cell lines over time following salinomycin treatment at the indicated dosage compared to 
0.01% DMSO vehicle control. B. Bar graphs showing altered cell cycle (Propidium Iodide staining) in A9M and MAF9 primary leukaemia 
cell lines over time following salinomycin treatment at the indicated dosage or 0.01% DMSO vehicle control. C. Representative morphology 
images of A9M and MAF9 primary leukaemia cell lines treated for 48 and 72 hours with salinomycin at the indicated dosages or 0.01% 
DMSO. Band neutrophil is highlighted with an arrow. Mean values ± S.E.M. of biological replicates (n=4) are plotted throughout. ***P < 
0.001, **P < 0.01, *P < 0.05, t-test. Scale bar = 4 μm.
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significance in the form of B-statistic (log-odds) or 
negative log
10
(Adjusted P-value) versus log
2
 expression 
(fold change) for each gene. Ultimately, only genes with 
−log
10
(Adjusted P-value) > 2 and log
2
(fold change) > 0.5 
were considered (Figure 4A). All samples and transcripts 
induced or repressed at log
2
 (fold change) of 0.5 or more 
(P ≤ 0.05) were subjected to hierarchical agglomerative 
clustering by treatment with salinomycin (Figure 4B, 
left panel). Clustering was based on a Euclidean distance 
and complete linkage as distance and linkage methods. 
Transcripts induced or repressed at log
2
(fold change) of 
0.5 or more (P ≤ 0.01) were sorted in ascending order by 
adjusted P-value. Twenty one probes, representing 18 
genes, were identified for further evaluation (Figure 4B, 
right panel, Supplementary Table S3).
Col4a1 was excluded due to insufficient expression 
(C
T
 > 35) and the remaining 17 genes were validated 
with high correlation (r2 = 0.901) to the array outputs 
for MAF9 (Supplementary Figure S4). All 17 genes 
were significantly differentially expressed (P < 0.05) 
in the MAF9 cells compared to control (Figure 4C) 
with lactotransferrin being the only gene with reduced 
expression following salinomycin treatment. qRT-PCR 
analysis of the salinomycin 17-gene signature was 
extended to A9M cells and over 50% (9/17) of the genes 
demonstrated differential expression to a significance level 
(P < 0.05).
The salinomycin 17-gene signature was further used 
to interrogate bioinformatic databases. Submission of the 
gene signature to GeneMania [19], a large association-
based database, identified functional networks, including 
positive regulation of immune response and protein 
serine/threonine kinase activity, based primarily on co-
expression with FDR values < 10-5 (Supplementary Figure 
S5). Submission of the translated 17-gene signature to 
the protein-protein interaction network STRING [20] 
identified three primary hubs (NF-kB, chemokine and 
DNA repair) centrally connected by Tnf, Mapk14 and 
Akt1 (Supplementary Figure S6A). Application of the 
signature to DAVID (The Database for Annotation, 
Visualization and Integrated Discovery) [21, 22] analysis 
identified the toll-like pathway (KEGG) with significance 
(P = 0.0063 corrected by the Benjamini-Hochberg method; 
Supplementary Figure S6B). Together, these analyses 
identified association of salinomycin treatment with 
primary immunomodulatory pathways.
Induction of sequestosome-1(p62) positive 
aggresomes/vesicles
Five of the genes identified as part of the 
salinomycin-induced signature in MAF9 cells, 
including sequestosome-1 (Sqstm1/p62), were highly 
significantly upregulated (P < 0.001) compared to control 
(Supplementary Table S3). Sqstm1 is associated with the 
formation of polyubiquitin-containing aggresome-like 
induced structures (ALIS), which resemble the vesicles 
observed in the salinomycin-treated leukemic cell lines 
(Figures 1C, 2C and 3C). To examine this further, human 
MLLr and both primary cell lines were treated with 
salinomycin and probed for expression of Sqstm1/p62. 
Treated cells showed cytoplasmic restricted Sqstm1/p62 
positivity, by co-immunofluorescence and DAPI staining, 
in a dose-dependent manner (Figure 5). Quantitative 
scoring demonstrated a marked increase in the proportion 
of salinomycin treated Sqstm1/p62 positive cells 
compared to vehicle control (Supplementary Figure S7) 
associated with modest increased expression of Atg7 and 
Beclin-1, particularly in the more sensitive MAF9 cells, 
as determined by western blot analysis (Supplementary 
Figure S8). Together, these data indicate activation of an 
autophagic response by AML/MLLr cells to low-dose 
salinomycin treatment.
Anti-leukemic effects of salinomycin in 
primary cells
Primary mouse models and patient samples 
were next used to examine the anti-leukemic activity 
of salinomycin. Normal bone marrow (mouse) and 
donor derived mobilized peripheral blood (human) 
cells served as controls to examine potential toxicity to 
normal hematopoietic cells. As for the generated mouse 
cell lines, a range of low dose salinomycin (10 nM to 
500 nM) was used to treat the corresponding primary 
leukemia cells (A9Mp and MAF9p, respectively). 
Myeloid colony formation for both primary leukemias 
was impaired in a dose dependent manner compared to 
controls (Figure 6A). To examine effects on leukemia 
maintenance, vehicle control or salinomycin treated 
primary leukemias were transplanted into recipient 
mice. Extension in survival was observed for both the 
early onset A9Mp (P = 0.0027) and late onset MAF9p 
cells (P = 0.002) treated with 500 nM salinomycin 
compared to controls (Figure 6B). The short extension 
in survival (~ 6 days) for the more aggressive A9M 
compared to the more sensitive MAF9 leukemias may 
reflect differences in cell of origin or repopulating cell 
numbers. Transplantation of salinomycin treated normal 
bone marrow cells had no deleterious effect on recipient 
mice within the time of evaluation (data not shown). 
Colony formation of mouse normal bone marrow (NBM) 
or normal mobilized peripheral blood (NMPB) was not 
markedly affected by salinomycin treatment (even at 500 
nM), whereas the ability to form colonies was impaired 
by 100 nM and inhibited by 500 nM salinomycin 
treatment in both human (hAML1-3) and mouse (A9Mp, 
MAF9p) primary leukemias (Figure 6C). Interestingly, 
both mouse and patient derived leukemia cells appear 
to retain metabolic activity (as seen by incorporation of 
the INT stain) but the ability to form small clusters or 
colonies is impaired.
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Figure 4: Differential gene expression in treated MAF9 cells. A. Volcano plots of significance for each of 24,326 probes from 
salinomycin (75 nM and 100 nM) treated MAF9 cells in the form of B-statistic (log-odds) or negative log
10
 (Adjusted P-value) versus log
2
 
(fold change) compared to 0.01% DMSO. Ultimately only genes with −log
10
 (Adjusted P-value) > 2 and log
2
 (fold change) > 0.5 were 
considered (marked by a red box). B. Hierarchical agglomerative clustered heatmaps of samples and transcripts induced or repressed at 
log
2
 (fold change) of 0.5 or more (P ≤ 0.05) (left panel) were sorted in ascending order (n=18 genes) by adjusted P-value to P ≤ 0.01 (right 
panel). Hierarchical clustering was based on a Euclidean distance and complete linkage as distance and linkage methods. C. Bar graph 
demonstrating validated expression of 17 of the 18 genes of interest as measured by real-time qRT-PCR. Mean relative expression (-ΔΔC
T
) 
values ± S.E.M of biological replicates (n=4) were plotted. ***P < 0.001, **P < 0.01, *P < 0.05, t-test.
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DISCUSSION
Novel approaches to drug discovery for 
hematological malignancies are essential to take advantage 
of advances made in molecular classification over the 
last decade. Drug repurposing represents an attractive 
and economical option in which a novel application for 
an existing drug is indicated e.g. Metformin, the anti-
type 2 diabetes mellitus drug, was recently found to 
have anti-neoplastic effects in several tissues including 
gynecological cancers [23]. Salinomycin is a polyether 
antibiotic with promising anti-cancer properties [7, 8, 12, 
15], albeit at the micromole level with associated potential 
toxicities [24, 25]. A specific study on its potential clinical 
use in the acute leukemia context has not been reported.
Here, we investigated the anti-leukemic effects 
of low dose (sub-micromole) salinomycin in human 
and murine pre-clinical models, of AML and MLLr, 
including primary leukemia cells. Low dose salinomycin 
treatment resulted in reduced cell viability, increased 
apoptosis, vesicle formation and differentiation. A greater 
sensitivity was observed throughout for MLLr cells. The 
time and dose-dependent manner of the salinomycin 
effects indicated a biological response. Gene expression 
profiling and validation of the most sensitive murine 
MLLr cells revealed a salinomycin induced 17-gene 
signature, subsequently analyzed in the murine AML 
cells. Two of the genes verified in both primary cell lines, 
Klf6 and Ddit3, are markers of oxidative stress recently 
reported as upregulated by salinomycin in prostate cancer 
cells [26]. An additional gene identified, p62/Sqstm1, is 
required for aggresome formation linked to degradation of 
ubiquitinated proteins by autophagy [27]. Further analysis 
confirmed increased SQSTM1-positive aggresome 
formation and increased expression of Atg7 and Beclin-1 
in salinomycin treated leukemic cells. Salinomycin 
has been reported to induce autophagy in other cancers 
[28–30]. However, whether this response is cancer cell 
protective or destructive requires further investigation. 
SQSTM1 was recently shown to shuttle polyubiquitinated 
proteins to nuclear promyelocytic leukemia bodies [31], 
and a specific role in this context may warrant further 
examination.
Submission of the gene signature to online 
bioinformatics databases identified several pathways 
and network hubs including: positive regulation of 
immune response and serine/threonine kinase activity 
(GeneMania); NF-kB, DNA-damage and chemokine 
hubs (STRING) and the Toll-like receptor pathway 
(DAVID). Together these analyses indicate activation 
of an immunomodulatory response by salinomycin 
treatment. Immunomodulation is well established as 
Figure 5: Induction of Sequestosome-1(p62) positive aggresomes/vesicles. Combined immunofluorescence staining of 
SQSTM1/p62 with Alexa Fluor and DAPI depicting accumulation of cytoplasmic aggresomes/vesicles in MLLr, A9M and MAF9 cells 
treated with salinomycin for 48 hours at the indicated dosages or 0.01% DMSO. Representative images were taken using an x60 objective.
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Figure 6: Anti-leukemic effects of salinomycin in primary cells. A. Bar graphs showing decreased myeloid colony formation in 
untreated A9Mp and MAF9p primary mouse leukemia cells or following salinomycin treatment at the indicated dosage or 0.01% DMSO 
vehicle control. B. Kaplan Meier plots demonstrate extended survival in recipient mice (n=5 per group) following transplantation of 
salinomycin treated A9Mp or MAF9p primary leukemia cells compared to untreated or 0.01% DMSO vehicle controls. P-values, Log-rank 
(Mantel-Cox) Test. C. Representative images of colony formation of human normal mobilized peripheral blood (NmPB), patient samples 
hAML-1(#207), hAML-2 (#312), mouse normal bone marrow (NBM) and mouse AML (A9Mp) following salinomycin treatment at the 
indicated dosage or 0.01% DMSO vehicle control. Colonies were stained with 1 mg/ml p-iodonitrotetrazolium violet for 16 hours and 
images captured at x2 using an inverted microscope. Scale bar = 4 μm.
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both a cellular and molecular therapy in hematological 
malignancies, including leukemia [32–34]. Specifically, 
activation of Toll-like receptor pathways promotes 
differentiation and growth inhibition in AML [35] and 
demonstrates efficacy in combination with anti-multiple 
myeloma agents including bortezomib, lenalidomide, 
melphalan or vorinostat [36]. Activation of an immune 
response may also reflect inherent inhibition of these 
pathways in MLLr and HOXA9-Meis-induced malignant 
cells, as recently reported for MN1 [37], and highlight a 
potential therapeutic role for salinomycin in these specific 
leukemias. The specific loss of colony formation of 
primary leukemia cells and associated loss of repopulating 
ability in vivo supports the reactivation of differentiation 
pathways by low dose salinomycin treatment. The fact 
that cells remain metabolically active yet incapable of 
forming colonies may also reflect subtle differences in 
mitochondrial and biosynthesis requirements for AML 
cells that are susceptible to antibiotics and can be exploited 
[37–42].
Indeed, association with chemotherapy [43] or 
combination with experimental therapies, including 
histone deacetylase inhibitors, in the form of anticancer 
kits that exploit cytotoxic and neo-protection [44], as 
recently reported for solid tumours [45, 46], may provide 
the best method to exploit the observed anti-leukemic 
effects of salinomycin.
Together, the data demonstrates efficacy of non-toxic 
low dose salinomycin treatment against poor prognostic 
MLLr and AML and provides insights into the underlying 
molecular mechanisms. Further investigation of the 
mechanism and in vivo use of low dose salinomycin as a 
monotherapy or in combination with either chemotherapy 
or epigenetic modifiers is warranted, to provide the basis 
for future clinical application.
MATERIALS AND METHODS
Human cell lines, murine primary cell lines and 
leukemias and patient samples
Established, well-characterized and authenticated 
(DSMZ-2015), mycoplasma free human AML (OCI-
AML3, U937, HL60, NB4, and K562), t(9;11) MLLr 
(MOLM-13 and NOMO-1) and t(4;11) MLLr (MV4;11, 
and RS4;11) cell lines were maintained at 37°C with 
5% CO
2
 in Roswell Park Memorial Institute (RPMI) 
1640 medium supplemented with 10% Fetal Calf Serum 
(FCS), 2 mM L-glutamine, 100 U/ml penicillin and 100 
μg/ml streptomycin (RPMI-10; all Life Technologies, 
Paisley, UK). Low passage numbers of ATCC or 
DSMZ-authenticated stocks were used throughout. 
Murine leukemia cell lines were generated by retroviral 
transduction of lineage depleted (Lin-; Stem Cell 
Technologies, Vancouver, Canada) mouse primary 
bone marrow cells with MSCV-HOXA9-ires-Meis1 
(A9M) and MSCV-MLL-AF9 (MAF9), following serial 
replating (x3) in MethoCult™ GF M3434 medium (Stem 
Cell Technologies). Single colonies were selected and 
expanded for each leukemia, and maintained in RPMI-10 
supplemented with cytokine specific conditioned media (5 
ng/ml mIL-3, 5 ng/ml mIL-6, 50 ng/ml mSCF and 5 ng/
ml mGM-CSF; RPMI-10+) for over 2 months to become 
immortalized, as previously reported [47]. Cell lines 
generated were maintained at a density between 1-5x105 
cells per ml and seeded every two to three days. Primary 
leukemias derived from the same retroviral vectors 
(A9Mp and MAF9p) were also maintained in vivo. In 
accordance with the tenets of the Declaration of Helsinki, 
patient samples and mobilized peripheral blood cells were 
collected, anonymized and analyzed following informed 
consent and ethical committee (OREC-NI) approval. 
Mononuclear cells purified using Ficoll-Paque™ (GE 
Healthcare BioSciences AB, Uppsala, Sweden) gradient 
centrifugation, were frozen and stored prior to treatment.
Animals, vectors and transplantation assays
Male and female congenic donor CD45.1+ 
(C57Bl6/Pep3b) or (C57Bl/6-Ly5.1) and recipient 
CD45.2+ (C57Bl/6J) mice (10-16 weeks old) were bred 
and maintained in a specific pathogen-free (SPF) animal 
facility (BSU-QUB). Animal handling followed the 
guidelines of the UK Animals (Scientific Procedures) 
Act 1986. Experimental procedures were approved by 
the Animal Welfare Ethical Review Board (AWERB), 
Queen’s University Belfast. Age-matched, randomized, 
animals were used throughout. Generation of vesicular 
stomatitis virus-pseudotyped retroviruses, infection of 
hematopoietic cells and transplantation into mice were 
performed as previously described [48].
Cell viability, cell cycle and morphology
Human and murine cell lines were treated for up to 
72 hours in RPMI-10 or RPMI-10+ respectively containing 
either salinomycin (Sigma-Aldrich, Gillingham, UK) 
at the stated concentration or 0.01% DMSO as vehicle 
control. Cell viability was determined by CellTiter-Glo® 
(Promega, Madison, WI, USA). For cell cycle analysis, 
samples were fixed in 70% ethanol and DNA stained by 
Propidium Iodide (Sigma-Aldrich). DNA content was 
measured with an LSR II flow cytometer and analyzed 
using FACS DivaTM (BD Biosciences, Franklin Lakes, 
NJ, USA) or Cyflogic software (CyFlo Ltd, Turku, 
Finland). Cells were pelleted, re-suspended in 200 μl 
phosphate buffered saline (PBS), cytospun (28 x g) for 
5 minutes (Cytospin3, Thermo Shandon, Runcorn, UK) 
and stained with Modified Wright’s stain, for morphology 
analysis.
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Gene expression profiling
Total RNA was isolated using Trizol® (Life 
Technologies), and its quality was assessed using Agilent 
RNA 6000 Nano chip and Agilent 2100 Bioanalyzer 
(Agilent Technologies, Santa Clara, CA) according to the 
manufacturer’s instructions. RNA integrity (RIN) values 
of >9 were obtained for all samples prior to application 
to the Mouse Ref-8 expression v.2 BeadArray (Illumina, 
San Diego, CA), according to the manufacturer’s 
instructions. Briefly, 550 ng of each RNA sample was 
reverse transcribed then in vitro transcribed to generate 
biotinylated cRNAs. Aliquots of labelled cRNAs (750 ng) 
were then hybridized to the BeadArray for 16-18 hours 
at 58°C. Signal detection was achieved using Amersham 
fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, 
Little Chalfont, UK) and scanned images obtained using 
the Illumina BeadArray confocal scanner. Bead level data 
of biological triplicates were transformed to log
2
 scale, 
normalized (quantile method) using beadarray R package 
[49] and annotated (Gene Symbols, Names, Entrez IDs, 
and Probe Quality Grades) using illuminaMousev2.db 
R package [50]. Probes with poor quality grades were 
removed. Differential expression was then assessed 
by linear regression followed by parametric empirical 
Bayes analysis using limma R package [51] and output 
obtained by plotting significance versus log
2
 expression 
(fold change). Genes with expression ratios above 
log
2
(0.5)-fold between treatments and control (P < 0.05 
and P < 0.01) were identified. False discovery rates 
(FDR) were controlled using the Benjamini-Hochberg 
algorithm. Hierarchical clustering with complete linkage 
and Euclidean distance, as a measure of similarity, was 
performed.
qRT-PCR validation of beadarray data
Total RNA isolated from salinomycin or vehicle 
treated MAF9 and A9M cells was converted to cDNA 
[9]. Expression of 18 candidate genes with Peptidylprolyl 
isomerase A 1 (Ppia1) as endogenous control was 
quantified using technical duplicates of biological 
replicates (n=4). Genes and corresponding primers are 
listed (Supplementary Table S4). Assays were performed 
with FastStart Universal SYBR Green Master Mix 
(Roche) on the Applied Biosystems 7900HT Fast Real-
Time PCR System using Sequence Detection System 
(SDS v2.3) software as per manufacturers’ protocols. 
Technical duplicates with standard deviations <0.6 
C
T
 were averaged, else a single value closest to other 
biological replicates was used.
Data were processed as reported previously [52]. 
Briefly, mean ΔC
T
 values and standard errors calculated 
for each control and treatment group were normalized 
to yield −ΔΔC
T
 (=ΔC
T
control −ΔC
T
treatment) values, which 
effectively constitute log
2
 fold changes in expression of 
genes of interest in treated samples compared to control.
Immunofluorescence
Treated and control cells were collected by 
centrifugation (107 x g), re-suspended in PBS, and 1 x 
105 cells cytospun (28 x g) onto glass slides (Cytospin3, 
Thermo Shandon Ltd., Runcorn, UK). Cells were fixed 
in 4% Paraformaldehyde (Sigma-Aldrich) for 15 minutes, 
washed (x 2) in PBS, permeabilized in 0.2% Triton X-100/
PBS (Sigma-Aldrich) for 15 minutes, then incubated in 3% 
Bovine Serum Albumin Fraction V (BSA; Sigma Aldrich) 
for 30 minutes, all at room temperature. SQSTM1/p62 
Alexa Fluor monoclonal antibody (Clone 864807; R&D 
Systems, Abingdon, UK) was diluted 1:10 in 3% BSA/
PBS, as per the manufacturer’s instructions, and slides 
were incubated overnight at 4°C in a humidified chamber. 
Following primary antibody labelling, slides were washed 
(x3) in PBS, air-dried, and mounting medium containing 
4',6-diamidino-2-phenylindole (DAPI) applied prior to 
coverslip application. Slides were stored at 4°C prior to 
image capture using a Nikon Eclipse Ti microscope (x60 
objective) (Nikon, Surrey, UK).
Salinomycin treatment of primary leukemias
Fresh primary murine leukemia or rapidly thawed 
primary AML patient bone marrow and mobilized 
peripheral blood samples were allowed to recover in 
RPMI-10+ or RPMI-10 respectively. Primary cells were 
treated with salinomycin or DMSO for 16 hours in 
liquid culture then plated in methylcellulose. Similarly 
treated human cells were seeded at 1 x 105/ml in 
MethoCult™ H4434 Classic (Stem Cell Technologies) 
and treated mouse leukemias were either seeded at 5 x 
105/ml in MethoCult™ GF M3434 medium (Stem Cell 
Technologies) or directly transplanted (5 x 105 cells) into 
sub-lethally irradiated (850 cGy) recipient mice. Recipient 
mice were followed for up to 80 days, or disease endpoint, 
at which point necropsy was performed.
Methylcellulose assays, staining and imaging
Methylcellulose cultures were maintained at 37°C 
with 5% CO
2
 for up to 10 days when colony formation, 
colony counts, and images were captured and analyzed. 
Colony staining with 1 mg/ml p-iodonitrotetrazolium 
violet (INT, Sigma-Aldrich, Gillingham, UK) for 16 hours 
enabled visualization of colonies and metabolic activity.
Statistical analysis
Student’s t-tests were performed using GraphPad 
Prism software v5.0 (GraphPad Software, La Jolla, CA, 
Oncotarget12www.impactjournals.com/oncotarget
USA). Sample sizes of similar variance (n ≥ 3 for cell 
lines and n ≥ 5 for animal studies) were selected based on 
previous experience to provide sufficient statistical power. 
Means ± SEM were plotted and significance denoted by 
the value or as * p ≤ 0.05; ** p ≤ 0.01, *** p ≤ 0.001 
throughout.
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